<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01374568</url>
  </required_header>
  <id_info>
    <org_study_id>UAB F100317002</org_study_id>
    <nct_id>NCT01374568</nct_id>
  </id_info>
  <brief_title>Changes in Bone Turnover With Increased Incretin Hormone Exposure</brief_title>
  <acronym>DRTC</acronym>
  <official_title>Changes in Bone Turnover With Increased Incretin Hormone Exposure (UAB Diabetes Research and Training Center Pilot and Feasibility Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if the use of sitagliptin increases bone formation
      and reduces bone turnover in postmenopausal women with type 2 diabetes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with Type 2 Diabetes Mellitus (T2DM) are at an increased risk of fracture, despite
      having bone mineral density (BMD) similar to age and sex matched cohorts. Recent studies have
      indicated that changes in incretin (INtestinal seCRETion of INsulin) hormones in the setting
      of T2DM may play a role in bone metabolism. Two of these incretin hormones, gastric
      inhibitory polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), have been shown to be
      involved in bone turnover regulation, in addition to their effect in increasing insulin
      secretion and decreasing glucagon secretion in a glucose-dependent manner. In addition, the
      rise in glucagon-like peptide-2 (GLP-2) in the postprandial state has been found to have a
      direct effect on reduced bone resorption in a non-fasting state and treatment with GLP-2
      improved BMD in postmenopausal women. Due to their glucose lowering effects, incretins have
      been a therapeutic target for the treatment of T2DM through GLP-1 receptor analogs or
      inhibition of incretin metabolism via dipeptidyl peptidase 4 (DPP-4) inhibitors (i.e.
      sitagliptin). Inhibition of DPP-4 leads to an approximate doubling of GLP-1 and GIP levels
      but also leads to reduced breakdown of GLP-2.

      Less is known about the effect of incretin-directed therapies, specifically sitagliptin, and
      bone metabolism. To our knowledge, two studies have looked at the direct effects of currently
      available incretin-directed therapies on bone metabolism. Exenatide (a GLP-1 analog)
      treatment of insulin resistant and type 2 diabetic rats resulted in osteogenic effects with
      increased osteocalcin levels following treatment. In a study of female non-diabetic
      Sprague-Dawley rats treated with pioglitazone, rosiglitazone, sitagliptin, vs. placebo, no
      significant change in bone mineral density was seen in the sitagliptin or placebo treated
      rats (compared to significant loss of bone mineral density in the TZD groups). Even fewer
      published studies are available evaluating changes in bone metabolism with the use of
      incretin hormones in humans. The majority of the human studies have been completed with
      GLP-2. These studies show a dose-dependent effect of GLP-2 on bone resorption and,
      preliminarily, show improved bone mineral density in postmenopausal women treated with GLP-2.
      However, the changes in incretin activity vary in persons with glucose intolerance and T2DM.
      Therefore, it is important to understand the potential effects of these medications on bone
      metabolism in persons prescribed these medications for treatment of their T2DM.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study closed by sponsor. Funding ended.
  </why_stopped>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">July 6, 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bone Turnover in Subjects Treated With Sitagliptin When Compared to Those Treated With Placebo.</measure>
    <time_frame>8 weeks</time_frame>
    <description>Bone turnover assessed using change in TRACP5b over 8 weeks of treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bone Turnover in Subjects Treated With Sitagliptin When Compared to Those Treated With Placebo</measure>
    <time_frame>8 WEEKS</time_frame>
    <description>Bone turnover assessed using change in bone-specific alkaline phosphatase (BAP) over 8 weeks of treatment.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>sitagliptin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sitagliptin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sitagliptin</intervention_name>
    <description>sitagliptin 100mg daily</description>
    <arm_group_label>sitagliptin</arm_group_label>
    <other_name>Januvia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1 pill daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Postmenopausal women (as defined by age &gt;55 years old or amenorrhea for &gt;1years)

          -  Type 2 DM currently not on diabetes-specific medication(s) or treated with monotherapy
             of metformin or a sulfonylurea. Patients treated with insulin monotherapy will also be
             eligible if the total daily dose of insulin is &lt;10units.

          -  Hemoglobin A1c (HbA1c) of 6.5-9.0%

        Exclusion Criteria:

          -  Use of an incretin mimetic (i.e. exenatide), a DPP-4 inhibitor (i.e. sitagliptin,
             saxagliptin), a thiazolidinedione, or oral glucocorticoids in the 6 months prior to
             the study will not be eligible

          -  Known osteoporosis or patients treated with an osteoporosis-specific medication
             (bisphosphonate, teriparatide) or estrogen (including Selective Estrogen Receptor
             Modulators (SERMs)) or those who anticipate imminent treatment with one of these
             medications will be excluded from the study

          -  Chronic kidney disease (calculated GFR &lt;30 ml/min) or a disease known to affect bone
             turnover (i.e. Paget Disease, Osteogenesis Imperfecta, HIV) will be excluded from the
             study.

          -  History of pancreatitis
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amy Warriner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 10, 2011</study_first_submitted>
  <study_first_submitted_qc>June 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 16, 2011</study_first_posted>
  <results_first_submitted>January 18, 2017</results_first_submitted>
  <results_first_submitted_qc>May 2, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">May 31, 2017</results_first_posted>
  <last_update_submitted>June 23, 2017</last_update_submitted>
  <last_update_submitted_qc>June 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>Amy H. Warriner</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Type 2 diabetes</keyword>
  <keyword>sitagliptin</keyword>
  <keyword>Januvia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Sitagliptin Phosphate</mesh_term>
    <mesh_term>Gastric Inhibitory Polypeptide</mesh_term>
    <mesh_term>Incretins</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Postmenopausal women with diabetes mellitus on no medications or metformin treatment alone were recruited from an outpatient clinic setting.</recruitment_details>
      <pre_assignment_details>Potential participants completed a screening visit to ensure all study inclusion criteria were met. If on metformin at the screening visit, the metformin was discontinued. Potential participants presented 1 month later for the baseline visit and for randomization.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Sitagliptin</title>
          <description>Sitagliptin
sitagliptin: sitagliptin 100mg daily</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo
Placebo: 1 pill daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lab unable to analyze BTM</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>6 patients were screened. 1 patient did not return for baseline visit. 5 patients were provided study medication.</population>
      <group_list>
        <group group_id="B1">
          <title>Sitagliptin</title>
          <description>Sitagliptin
sitagliptin: sitagliptin 100mg daily</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo
Placebo: 1 pill daily</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="5"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.5" spread="6.5"/>
                    <measurement group_id="B2" value="61.0" spread="8.3"/>
                    <measurement group_id="B3" value="61.0" spread="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Systolic Blood Pressure</title>
          <units>mmHg</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="119" spread="11.0"/>
                    <measurement group_id="B2" value="130" spread="10.0"/>
                    <measurement group_id="B3" value="130" spread="12.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diastolic Blood Pressure</title>
          <units>mmHg</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="82" spread="8"/>
                    <measurement group_id="B2" value="78" spread="6.2"/>
                    <measurement group_id="B3" value="78" spread="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Bone Turnover in Subjects Treated With Sitagliptin When Compared to Those Treated With Placebo.</title>
        <description>Bone turnover assessed using change in TRACP5b over 8 weeks of treatment.</description>
        <time_frame>8 weeks</time_frame>
        <population>The difference between the bone turnover markers TRACP5b from baseline to end of study were calculated for treatment and placebo groups. Serum samples were not available for one placebo participant at baseline and for one placebo patient at end of study. As a result we were unable to analyze the 2 participants with missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin</title>
            <description>Sitagliptin
sitagliptin: sitagliptin 100mg daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo
Placebo: 1 pill daily</description>
          </group>
        </group_list>
        <measure>
          <title>Bone Turnover in Subjects Treated With Sitagliptin When Compared to Those Treated With Placebo.</title>
          <description>Bone turnover assessed using change in TRACP5b over 8 weeks of treatment.</description>
          <population>The difference between the bone turnover markers TRACP5b from baseline to end of study were calculated for treatment and placebo groups. Serum samples were not available for one placebo participant at baseline and for one placebo patient at end of study. As a result we were unable to analyze the 2 participants with missing data.</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.25" spread="0.07"/>
                    <measurement group_id="O2" value="0.30" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Bone Turnover in Subjects Treated With Sitagliptin When Compared to Those Treated With Placebo</title>
        <description>Bone turnover assessed using change in bone-specific alkaline phosphatase (BAP) over 8 weeks of treatment.</description>
        <time_frame>8 WEEKS</time_frame>
        <population>The difference between the bone turnover markers bone alkaline phosphatase (BAP) from baseline to end of study were calculated for treatment and placebo groups. Serum samples were not available for one placebo participant at baseline and for one placebo patient at end of study.</population>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin</title>
            <description>Sitagliptin
sitagliptin: sitagliptin 100mg daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo
Placebo: 1 pill daily</description>
          </group>
        </group_list>
        <measure>
          <title>Bone Turnover in Subjects Treated With Sitagliptin When Compared to Those Treated With Placebo</title>
          <description>Bone turnover assessed using change in bone-specific alkaline phosphatase (BAP) over 8 weeks of treatment.</description>
          <population>The difference between the bone turnover markers bone alkaline phosphatase (BAP) from baseline to end of study were calculated for treatment and placebo groups. Serum samples were not available for one placebo participant at baseline and for one placebo patient at end of study.</population>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" spread="1.34"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>8 weeks</time_frame>
      <desc>Two participants not analyzed due missing BTM at different time points. Statistician unable to include missing data due to small enrollment numbers.</desc>
      <group_list>
        <group group_id="E1">
          <title>Sitagliptin</title>
          <description>Sitagliptin
sitagliptin: sitagliptin 100mg daily</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo
Placebo: 1 pill daily</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Study was closed due to end of funding prior to recruitment of target participants. Small participant number limits data analysis. We were unable to obtain additional funding to complete the study.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Amy Warriner</name_or_title>
      <organization>UAB</organization>
      <phone>2059964004</phone>
      <email>awarriner@uabmc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

